Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials -

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers
Summary
Findings from these trials (n=709) showed no benefit in overall survival for all patients with the use of afatinib, but the drug did result in improvements in overall survival compared with platinum-doublet chemotherapy in patients with EGFR del19-positive lung adenocarcinoma.
UKMi comment
In LUX-Lung 6, median overall survival was 23.1 months (95% CI 20.4–27.3) in the afatinib group and 23•5 months (18•0–25•6) in the gemcitabine-cisplatin group (HR 0.93, 95% CI 0.72–1.22, p=0.61). However, in preplanned analyses, overall survival was significantly longer for patients with del19-positive tumours in the afatinib group than in the chemotherapy group in both trials: in LUX-Lung 3, median overall survival was 33.3 months (95% CI 26.8–41.5) in the afatinib group versus 21.1 months (16.3–30.7) in the chemotherapy group (HR 0.54, 95% CI 0.36–0.79, p=0.0015); in LUX-Lung 6, it was 31.4 months (95% CI 24.2–35.3) versus 18•4 months (14.6–25.6), respectively (HR 0.64, 95% CI 0.44–0.94, p=0.023).
Related links: Editorial